Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, open labeled, single arm study to determine effectiveness and safety
of chemoembolization with Irinotecan-Eluting Bead(DEBIRI) in the treatment of unresectable
liver metastases in patients with colorectal cancer after chemotherapy failure.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital